

References

- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer <https://www.nccn.org>
- SOLO-1: Moore K et al. 7-year update. J Clin Oncol 2023. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9870219/>
- PRIMA: González-Martín A et al. N Engl J Med 2019;381:2391–2402. <https://pubmed.ncbi.nlm.nih.gov/31562799/>
- PAOLA-1: Ray-Coquard I et al. N Engl J Med 2019;381:2416–2428. <https://pubmed.ncbi.nlm.nih.gov/31851799/>
- ATHENA-MONO: Colombo N et al. J Clin Oncol 2022. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9746782/>
- SOLO-1: Moore K et al. 7-year update. J Clin Oncol 2023. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9870219/>
- PRIMA: González-Martín A et al. N Engl J Med 2019;381:2391–2402. <https://pubmed.ncbi.nlm.nih.gov/31562799/>
- PAOLA-1: Ray-Coquard I et al. N Engl J Med 2019;381:2416–2428. <https://pubmed.ncbi.nlm.nih.gov/31851799/>
- ATHENA-MONO: Colombo N et al. J Clin Oncol 2022. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9746782/>
- FDA approval & summary — Mirvetuximab soravtansine (Elahere) — FDA approval page (Mar 2024).
- Moore KN et al., SORAYA trial (mirvetuximab soravtansine in FR α -high platinum-resistant ovarian cancer). PubMed PMID: 36716407. <https://pubmed.ncbi.nlm.nih.gov/36716407/>
- Moore KN et al. MIRASOL trial Mirvetuximab Soravtansine in FR α -Positive, Platinum-Resistant Ovarian Cancer <https://www.nejm.org/doi/full/10.1056/NEJMoa2309169>
- Gershenson DM, Slomovitz BM, Ivy SP, et al. Phase 2 RAMP 201 trial of avutometinib (VS-6766) \pm defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Presented at: ESMO / SGO / ASCO
- Gershenson DM et al., Trametinib vs physician's choice in recurrent LGSOC (LOGS/GOG-281). Lancet (open access/PMC). <https://pmc.ncbi.nlm.nih.gov/articles/PMC8819271/>